Zentynel is a venture capital fund with an investment focus specializing in biotechnology that arose from the convergence of Fundacion Ciencia Vida and Venturance Alternative Assets
We are creating a new generation of science and business funds to address the world’s greatest health and food challenges. We specialize in life sciences companies with high growth potential.
About Zentynel
Frontier investments
We are a joint venture of two leading players in science and business, complementing our skills to lead the fourth industrial revolution.
Venturance Alternative Assets
A fund manager specialized in alternative assets and consulting. Created in 2010, Venturance manages Private Equity, Venture Captial and other assets for more than US$ 250 million. It has experienced professionals from the financial, private equity and science and technology based ventures sectors.
Fundación Ciencia & Vida
Founded in Chile in 1996, FCV is a private research center focused on life sciences. The Foundation has a long history of knowledge development, intellectual property and partnerships with other research centers (such as the University of California San Francisco and the Curie Institute) and biotechnology companies, many of which are housed at its Science and Business Campus.
Our team
The Zentynel Fund is managed by five partners. Each of them has extensive experience in the biotechnology sector, having developed and managed companies and/or investment funds in this industry.
With more than two decades of experience in investment and development of biotech companies, Cristián has been CEO, Director of Companies and Research Centers, such as Fundación Ciencia & Vida, Nova Mineralis, Ingalfarma, Phage Labs, among others.
LinkedIn
With over a decade of experience working in startup development, Pablo is a Director of the Alerce Fund and a board member of Andes Ag, GeneproDX, Done Properly, Polynatural, among other companies.
LinkedIn
With more than twenty years of experience in investment and development of alternative assets, Roberto is co-founder of Venturance Investments and member of the board of directors of Clínica Alemana de Santiago, Bbosch, Lippi and Streat Burger, among others.
LinkedIn
Bernardita has more than thirty years of experience in regulatory affairs and intellectual property in biomedical companies. She is president and co-founder of Fundación Ciencia y Vida. She also serves on the boards of Fundación Chile, Universidad Andrés Bello, Comunidad Mujer and other organizations.
LinkedIn
After more than four decades of investment and business development in the biotechnology industry, Pablo has developed many cutting-edge medical technologies, such as the hepatitis B vaccine. He co-founded Chiron Corporation in 1982, one of the industry’s early pioneers in genetic engineering. In 2005, his company was acquired by Novartis for $8.9 billion.
Interesting
Healthtech invested by Zentynel
ISA RAISES MORE THAN US$ 6 MILLION
ISA was launched by the Pares family in 2017 with the goal of bringing quality care to users' homes while obtaining better prices through an asset-light model that reduces non-clinical costs, such as hotel and real estate, generating savings of up to 50% over traditional labs or clinics.
Mexican Agtech
MICROTERRA WAS SELECTED AMONG THE 50 MOST PROMISING CLIMATE TECH STARTUPS IN LATIN AMERICA AND THE CARIBBEAN.
MicroTerra is a Mexican agtech startup that is responsible for providing low-cost vegetable protein to feed fish, reducing nutrient pollution in the water. It was founded in 2018 and has raised more than US$500 thousand from funds such as IndieBio and SOSV. It has been part of our portfolio since 2022.
It was demonstrated by researchers at the University of Texas
A FUTURE MADE OF PROTEIN BATTERIES IS 100% POSSIBLE
Currently, more than 15 million tons of lithium are produced every year and a significant part is used to manufacture batteries, which represents a great environmental challenge. What options does science give us to face it? Researchers from the University of Texas published a paper in Nature where they demonstrated
Venture founded by a geneticist and a cardiologist (both Argentinean) and a Dutch patient
ZENTYNEL INVESTS US$ 700 THOUSAND IN MULTIPLAI
Multiplai developed a liquid biopsy for cardiovascular diseases, which makes it possible to analyze health and disease risk based on genetic information from a blood sample. The startup has a very high impact potential, they are targeting a very large market and are technically excellent.
In biotechnology sales are not everything
IS YOUR COMPANY GROWING IN THE RIGHT WAY?
In biotech, sales are not the most efficient indicator, so we want to share with you six keys that will let you know if your #biotech company is on the right track.
Its CEO is Colombian doctor María Artunduaga.
SAMAY RAISES MORE THAN US$1 MILLION IN SEED ROUND
Samay is an example of how applying technology in the right way, at the right time and answering the right questions can have a tremendous impact for millions of people around the world. How does it work? Through the installation of a small device to measure lung function that achieves 90% accuracy.
Challenges and Difficulties in Science Funding
THE CHALLENGE OF CREATING A NATION WITH MORE SCIENCE
This is the title of the column by our General Partner, Cristian Hernández published in La Tercera. In it, he reflects on the challenges and difficulties regarding public funding for R&D in Chile, a country with many needs, in which a smaller proportion of resources is allocated to science, innovation and technology.
Fund of funds widely recognized in the region
ANCHOR INVESTOR: SPECTRA INVESTMENTS
Based in Sao Paulo, Spectra Investments is a fund of funds widely recognized in the region and manages a portfolio of more than US$1 billion. Together with Zentynel, it has joined the challenge to do so in the biotech industry as one of our anchor investors.
Organized by SOFOFA HUB
PABLO FERNANDEZ SPOKE AT THE SEMINAR “BIOTECHNOLOGY AND BUSINESS”.
Our general partner, Pablo Fernandez, was in a panel specialized in how biotechnology can solve the challenges of companies, accompanied by prominent opinion leaders of the Biotech industry.
Healthtech invested by Zentynel
ISA RAISES MORE THAN US$ 6 MILLION
ISA was launched by the Pares family in 2017 with the goal of bringing quality care to users' homes while obtaining better prices through an asset-light model that reduces non-clinical costs, such as hotel and real estate, generating savings of up to 50% over traditional labs or clinics.
Mexican Agtech
MICROTERRA WAS SELECTED AMONG THE 50 MOST PROMISING CLIMATE TECH STARTUPS IN LATIN AMERICA AND THE CARIBBEAN.
MicroTerra is a Mexican agtech startup that is responsible for providing low-cost vegetable protein to feed fish, reducing nutrient pollution in the water. It was founded in 2018 and has raised more than US$500 thousand from funds such as IndieBio and SOSV. It has been part of our portfolio since 2022.
It was demonstrated by researchers at the University of Texas
A FUTURE MADE OF PROTEIN BATTERIES IS 100% POSSIBLE
Currently, more than 15 million tons of lithium are produced every year and a significant part is used to manufacture batteries, which represents a great environmental challenge. What options does science give us to face it? Researchers from the University of Texas published a paper in Nature where they demonstrated
Venture founded by a geneticist and a cardiologist (both Argentinean) and a Dutch patient
ZENTYNEL INVESTS US$ 700 THOUSAND IN MULTIPLAI
Multiplai developed a liquid biopsy for cardiovascular diseases, which makes it possible to analyze health and disease risk based on genetic information from a blood sample. The startup has a very high impact potential, they are targeting a very large market and are technically excellent.
In biotechnology sales are not everything
IS YOUR COMPANY GROWING IN THE RIGHT WAY?
In biotech, sales are not the most efficient indicator, so we want to share with you six keys that will let you know if your #biotech company is on the right track.
Its CEO is Colombian doctor María Artunduaga.
SAMAY RAISES MORE THAN US$1 MILLION IN SEED ROUND
Samay is an example of how applying technology in the right way, at the right time and answering the right questions can have a tremendous impact for millions of people around the world. How does it work? Through the installation of a small device to measure lung function that achieves 90% accuracy.
Challenges and Difficulties in Science Funding
THE CHALLENGE OF CREATING A NATION WITH MORE SCIENCE
This is the title of the column by our General Partner, Cristian Hernández published in La Tercera. In it, he reflects on the challenges and difficulties regarding public funding for R&D in Chile, a country with many needs, in which a smaller proportion of resources is allocated to science, innovation and technology.
Fund of funds widely recognized in the region
ANCHOR INVESTOR: SPECTRA INVESTMENTS
Based in Sao Paulo, Spectra Investments is a fund of funds widely recognized in the region and manages a portfolio of more than US$1 billion. Together with Zentynel, it has joined the challenge to do so in the biotech industry as one of our anchor investors.
Organized by SOFOFA HUB
PABLO FERNANDEZ SPOKE AT THE SEMINAR “BIOTECHNOLOGY AND BUSINESS”.
Our general partner, Pablo Fernandez, was in a panel specialized in how biotechnology can solve the challenges of companies, accompanied by prominent opinion leaders of the Biotech industry.
